Compare Aurora Cannabis Inc (ACB) vs Manhattan Associates Inc (MANH) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

MANH trades at $153.81, up 1.83% today, with a bullish technical outlook supported by moving averages and strong support at $150. The company demonstrates robust profitability with a 19.68% net margin and has beaten earnings estimates for three consecutive quarters. However, valuation ratios appear elevated with a P/E of 43.1, while ongoing legal investigations pose sentiment risks.

The stock offers upside to the $192.80 consensus price target but faces headwinds from high valuation multiples and legal uncertainties. Earnings growth and cloud strategy execution remain key catalysts, though investors must weigh these against potential dilution from the fiduciary duty investigations highlighted repeatedly in recent news.